Organization
Janssen Pharmaceuticals, Inc.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Janssen Pharmaceuticals, Inc.
... studies," said Paul Burton, MD, PhD, FACC, Vice President, Medical Affairs, Janssen Pharmaceuticals, Inc. "These FDA results yet again confirm the positive benefit-risk profile of ...
... these allegations and look forward to the opportunity to present our defense.” Janssen Pharmaceuticals called the allegations in the lawsuit unfounded and said its products ...
... TITUSVILLE - Janssen Pharmaceuticals, Inc., today announced INVEGA SUSTENNA (paliperidone palmitate), a once-monthly schizophrenia treatment, is ...
... research, today announced it has entered into a collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen). Under the terms of the agreement, Beacon and Janssen will ...
... Janssen Pharmaceuticals, Inc., today announced INVEGA SUSTENNA® (paliperidone palmitate), a once-monthly schizophrenia treatment, is ...
... amputees after the FDA concludes that Johnson & Johnson, Co. and Janssen Pharmaceuticals, Inc.'s sodium-glucose co-transporter-2 (SGLT2) inhibitor diabetes treatment drugs Invokana, Invokamet, and Invokamet ...
... are Purdue Pharma, Abbott Laboratories, Teva Pharmaceuticals USA, Cephalon, Johnson & Johnson, Janssen Pharmaceuticals and Endo Health Solutions. Representatives of the companies defended their actions. ...
... names 23 defendants including manufacturers Purdue Pharma Inc., Cephalon Inc., and Janssen Pharmaceuticals, Inc., as well as distributors The McKesson Corp., Cardinal Health, Inc. and ...
... therapeutics for the treatment of myelofibrosis. For instance, Geron Corporation and Janssen Pharmaceuticals, Inc. entered into a collaboration agreement, in which Geron Corporation granted an ...
... delivered a landmark decision Tuesday in a Xarelto lawsuit , ordering Janssen Pharmaceuticals Inc. and Bayer Healthcare Pharmaceuticals Inc. to pay $27.8 million to an ...
... Medivir AB(Nasdaq Stockholm: MVIR) today announces that Janssen Pharmaceuticals Inc. (Janssen) has decided to terminate the license that it holds for ...
... Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Inc. (Janssen), previously reported Health Canada approval of Tremfya (guselkumab) for the treatment ...
... Health, Inc. (NASDAQ: GHDX) today announced a multi-year research collaboration agreement with Janssen Pharmaceuticals to evaluate the Oncotype DX Genomic Prostate Score(TM) (GPS(TM)) test for ...
... MorphoSys AG / Key word(s): Regulatory Approval MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) for the Treatment of Moderate-to-Severe Plaque ...
... Co. Inc.; Teva Pharmaceuticals USA Inc.; Cephalon Inc.; Johnson & Johnson; Janssen Pharmaceuticals Inc.; Ortho-McNeil-Janssen Pharmaceuticals Inc.; Janssen Pharmaceutica Inc.; Endo Health Solutions Inc.; Endo ...
... In August 2017, Cerecor sold full worldwide rights to CERC-501 to Janssen Pharmaceuticals, Inc. in exchange for initial gross proceeds of $ 25 million, of ...
... March 2015, with the jury finding that Johnson & Johnson and its Janssen Pharmaceuticals subsidiary had failed to properly warn patients and doctors that Risperdal ...
... bolstered our cash position by selling all rights for CERC-501 to Janssen Pharmaceuticals, Inc. ('Janssen') for $ 25 million plus the potential for a $ ...
... Co. Inc.; Teva Pharmaceuticals USA Inc.; Cephalon Inc.; Johnson & Johnson; Janssen Pharmaceuticals Inc.; Ortho-McNeil-Janssen Pharmaceuticals Inc.; Janssen Pharmaceutica Inc.; Endo Health Solutions Inc.; Endo ...
... bolstered our cash position by selling all rights for CERC-501 to Janssen Pharmaceuticals, Inc. ("Janssen") for $25 million plus the potential for a $20 million ...
... bolstered our cash position by selling all rights for CERC-501 to Janssen Pharmaceuticals, Inc. ("Janssen") for $25 million plus the potential for a $20 million ...
... VTE recurrence,' said Paul Burton, MD, PhD, FACC, Vice President, Medical Affairs, Janssen. 'The landmark EINSTEIN program results yet again demonstrate XARELTO is a safe ...
... Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) approved the ...
... at The Phoenician in Scottsdale, AZ. Vanessa Broadhurst, President, Cardiovascular & Metabolism, Janssen Pharmaceuticals and Scott White, President, Immunology, Janssen Pharmaceuticals will represent the Company ...
... of the worldwide license and collaboration arrangement on hepatitis C with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. ...
Want to see the full history on Janssen Pharmaceuticals, Inc.? Upgrade to RelSci Pro now!
Start My Free Trial